Richard Anthony Cunningham - 04 Apr 2025 Form 4 Insider Report for Anebulo Pharmaceuticals, Inc. (ANEB)

Role: Chief Executive Officer, Director
Signature: /s/ Daniel George, as attorney-in-fact
Issuer symbol: ANEB
Transactions as of: 04 Apr 2025
Transactions value $: $0
Form type: 4
Filing time: 07 Apr 2025, 21:41:34 UTC
Previous filing: 10 Dec 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANEB	Stock Option (right to buy)	Award	$0	+316,352		$0	316,352	04 Apr 2025	Common Stock	316,352	$1.02	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-sixteenth (1/16) of the shares subject to the option vested and became exercisable on April 4, 2025, with the remainder scheduled to vest and become exercisable in fifteen (15) equal quarterly installments on each July 15, October 15, January 15, and April 15 thereafter, vesting fully on January 15, 2029, in each case, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Content

One-sixteenth (1/16) of the shares subject to the option vested and became exercisable on April 4, 2025, with the remainder scheduled to vest and become exercisable in fifteen (15) equal quarterly installments on each July 15, October 15, January 15, and April 15 thereafter, vesting fully on January 15, 2029, in each case, subject to the Reporting Person's continued service to the Issuer through each vesting date.